FDA Approves ALS Drug on Phase 2 Data
The agency, under pressure from advocacy groups, considers uncertainty about efficacy to be acceptable.
NEWS
Up, and Down—Haptoglobin Moves APOE4 Risk in Mysterious Ways
The blood protein tempers APOE4 risk in E2 carriers yet accentuates it in E4 homozygote people.
LRRK2 Variants Keep α-Synuclein from Forming Tetramers
The Parkinson’s-related proteins promoted pathological hyperphosphorylation of α-synuclein.
In Mini-Pigs Missing SORL1, Endosomes Swell and Aβ Peptides Rise in CSF
The animals had no plaques or tangles, although they are still young.
Finally: Big Win on All Outcomes for Lecanemab in Phase 3 Topline Results
Drug sponsors Eisai and Biogen said they will apply for approval in Europe, the U.S., and Japan; more detailed data will be presented at CTAD.
Windfall Week for Trial Data: Papers on Crenezumab, Neflamapimod, Tofersen
Three drugs, targeting three different pathogenic mechanisms in Alzheimer's, dementia with Lewy bodies, and ALS, had trial data formally published this week.
Can 10,000 Steps a Day Keep Dementia at Bay?
Adults who hit this number were half as likely as their sedentary peers to develop dementia over seven years. Power walking for 30 minutes daily cut risk by 60 percent.
As Health Problems Pile Up, Dementia Climbs on Top of the Heap
According to findings from more than 200,000 people 60 and older, having multiple chronic diseases nearly doubles the risk of dementia within the next 12 years.
SPOTLIGHT
Dare We Say Breakthrough! Lecanemab Positive on All Endpoints
After 20 years of clinical trials of anti-amyloid therapies, finally, a Phase 3 trial has posted cleanly positive results across all endpoints. Eisai/Biogen announced topline results of their CLARITY trial, saying that it met the primary and all secondary outcomes with high statistical significance. This makes it highly likely that the FDA will approve this therapeutic antibody in 2023. For the first time in the history of Alzheimer’s care, patients will receive a disease-modifying treatment along with their diagnosis. The clinical benefit is small, and must be built upon. Even so, this moment marks a change in Alzheimer’s research.
Can 10,000 Steps a Day Keep Dementia at Bay?
Time to lace up those sneakers. Adults who power-walked 30 minutes per day slashed their dementia risk over the next seven years by 60 percent. A daily step count of 9,800 halved the odds. Walking just 3,800 steps per day edged down the risk of dementia by 25 percent.
Join The Conversation
Professional Resources
New in last 7 days
-
Grants
- New Items: 2
- Total Items: 527
-
Jobs
- New Items: 1
- Total Items: 51
-
Conference Calendar
- New Items: 1
- Total Items: 115
- Member Directory
Latest Comments